Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

The lowered sales forecast, which analysts called a “shocking guidance update,” contributed to a 23% drop in the cancer ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

The firm's analyst highlighted the solid momentum of Exact Sciences' Cologuard business, noting a Compound Annual Growth Rate (CAGR) of approximately 31% from 2021 to 2023 for the product.

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, has announced the company presenting modeling data evaluating the simulated benefit and burden of established CRC ...

Exact Sciences, which is behind brands Cologuard and Oncotype DX, said it will combine CancerSEEK with its scientific platform, clinical organization, and commercial infrastructure. The company ...

NOTE: Exact Sciences, Cologuard and Cologuard Plus are trademarks or registered ... are described in the Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent ...

NOTE: Exact Sciences, Cologuard and Cologuard Plus are trademarks ... Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and ...